Please upgrade your browser.
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
First Publically Presented Results of Industry-Leading Collaboration Aimed to Assess Prognosis for Early-Stage Renal Cell Carcinoma.
Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Abbott data being presented includes two oral presentations on elotuzumab, an antibody designed to bind to the CS1 glycoprotein, a highly expressed cell surface protein in multiple myeloma. Four separate studies of linifanib (ABT-869), which is being studied as an inhibitor of the VEGFR and PDGFR kinase pathways, in advanced renal cell cancer (RCC), advanced solid tumors, advanced hepatocellular carcinoma (HCC) and non small cell lung cancer (NSCLC), also will be presented.
A detailed analysis of the epigenetics -- factors controlling when and in what tissues genes are expressed -- of Wilms tumor reveals striking similarities to stem cells normally found in fetal kidneys.
Newly discovered markers cannot increase patient survival, rather their prognostic value supporting therapeutic decisions or new agents targeted at these new markers.
Small but decisive study highlights differences in clear- and non-clear cell subtypes.
Prometheus to Present New Data on Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting Read more: Prometheus to Present New Data on Proprietary Oncology Diagnostic Platform at ASCO Annual
Data will also be presented from independent studies of PROLEUKIN® (aldesleukin), a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic renal cell carcinoma.
When kidney cancer spreads to other body parts, patients usually receive a poor prognosis. A new Mayo Clinic study examined the benefits of surgical treatment of kidney cancer, specifically renal cell carcinoma . . .
Hysterectomy is associated with an approximately doubled risk. Hormonal factors or injury of the ureter during surgery were considered as possible causes.
In Europe the incidence of RCC has doubled in the period from 1975 to 2005. RCC accounted for 3777 deaths in the UK in 2006; male 2372, female 1820.
|NeonCRM by Neon One|